Pangaea Oncology, S.A. (BME:PANG)
Spain · Delayed Price · Currency is EUR 1.550
0.00 (0.00%)
Aug 6, 2026, 4:00 PM CET
Pangaea Oncology Revenue
In the year 2025, Pangaea Oncology had annual revenue of 14.52M EUR with 1.78% growth. Pangaea Oncology had revenue of 7.37M in the half year ending December 31, 2025, with 42.98% growth.
Revenue
14.52M
Revenue Growth
+1.78%
P/S Ratio
3.33
Revenue / Employee
n/a
Employees
165
Market Cap
55.67M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.52M | 253.93K | 1.78% |
| Dec 31, 2024 | 14.27M | 6.88M | 93.14% |
| Dec 31, 2023 | 7.39M | 3.02M | 69.15% |
| Dec 31, 2022 | 4.37M | -235.38K | -5.11% |
| Dec 31, 2021 | 4.60M | 503.64K | 12.29% |
| Dec 31, 2020 | 4.10M | 783.11K | 23.61% |
| Dec 31, 2019 | 3.32M | 258.18K | 8.44% |
| Dec 31, 2018 | 3.06M | 436.56K | 16.65% |
| Dec 31, 2017 | 2.62M | 103.47K | 4.11% |
| Dec 31, 2016 | 2.52M | 568.73K | 29.17% |
| Dec 31, 2015 | 1.95M | 232.24K | 13.52% |
| Dec 31, 2014 | 1.72M | -1.37M | -44.40% |
| Dec 31, 2013 | 3.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.42B |
| Almirall | 1.16B |
| Laboratorios Farmaceuticos Rovi | 773.05M |
| Faes Farma | 711.06M |
| Laboratorio Reig Jofre | 337.73M |
| Prim, S.A. | 251.89M |
| Atrys Health | 144.31M |
| Labiana Health | 76.44M |